Yarrow Bioscience Inc. (YARW)
YARW trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/0001566044-26-000002-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | YARW on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001566044 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $570K |
| Net income | -$26.5M |
| Operating income | -$29.7M |
| Net margin | -4646.1% |
| Operating margin | -5219.1% |
| Revenue growth | +13.8% |
| Cash | $24.0M |
| Total assets | $30.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 372.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-13 |
| Cash and burn | $22.9M cash; operating cash flow -$7.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 15,234,944 (2026-11-03); 13,957,324 three years earlier. 3y figure adjusted for splits (1-for-50 overall). | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest 1-for-50 on 2026-07-27 | Source 2026-07-27 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-09-11 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-11 |
| Auditor | Baker Tilly US, LLP, Tewksbury, Massachusetts, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 9,304,361 shares at the 2026-11-13 price; the latest SEC cover count is 15,234,944 as of 2026-11-03. One of the two share counts is stale. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $97K | -$3.0M | -$2.0M | $22.9M | $0 | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $86K | -$3.6M | -$4.1M | $24.6M | $0 | Needs four quarters | 10-Q 2026-05-15 |
| Q2 2025 2025-06-30 | $69K | -$5.8M | -$10.8M | $22.0M | $0 | $476K | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $202K | -$8.6M | -$11.5M | $28.2M | $0 | $605K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $84K | -$12.0M | -$9.0M | $19.9M | $0 | $501K | 10-K 2026-02-27 |
| Q3 2024 2024-09-30 | $121K | -$12.2M | -$8.5M | $16.3M | $0 | $493K | 10-Q 2024-11-07 |
| Q2 2024 2024-06-30 | $198K | -$9.4M | -$8.5M | $29.6M | $0 | $486K | 10-Q 2025-08-14 |
| Q1 2024 2024-03-31 | $98K | -$6.2M | -$8.0M | $19.1M | $0 | $423K | 10-Q 2025-05-08 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-11 |
| Latest annual report | 10-K | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2025-11-12 |
Source: SEC EDGAR submissions feed, 692 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +15.6% |
| 1 month | -3.1% |
| 3 months | -57.8% |
| Year to date | -37.8% |
| 1 year | -2.3% |
| From 52-week high | -60.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACIU | AC Immune SA | $2.09 | -1.88% | $212.7M |
| VOGX | Vogenx Inc | $14.38 | -13.74% | $213.6M |
| CYPH | Cypherpunk Technologies Inc. | $1.93 | +2.94% | $207.4M |
| SIGA | SIGA Technologies Inc. | $2.85 | +4.01% | $204.8M |
| DRUG | Bright Minds Biosciences Inc. | $22.61 | -2.16% | $222.0M |
| BCYC | Bicycle Therapeutics plc | $3.18 | -5.64% | $222.9M |
| GLSI | Greenwich LifeSciences Inc. | $13.76 | -7.90% | $202.0M |
| IMRX | Immuneering Corporation | $3.52 | -5.12% | $228.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier